VTU Technology GmbH
VTU Technology is a leading contract research and development company located in Austria, providing services for the fast track generation of high performance Pichia pastoris protein production strains and economically viable protein production processes for biopharmaceuticals and enzymes. The development activities include production strain generation, development of upstream and downstream processes as well as establishment of analytical procedures and production of protein samples.
VTU has established a broad range of tools and know-how for the generation of high performance Pichia processes. Exclusive proprietary technologies and profound experience of the VTU team lead to competitive production processes for a wide range of recombinant proteins including serum proteins, cytokines, Fc & HSA fusion proteins, Fabs & Ab derived fragments, scaffold proteins, vaccines and enzymes.
Judging from numerous completed and ongoing development projects, protein production processes developed in VTU´s labs have been shown to be robust and scalable facilitating sound technology transfer and straightforward implementation in large scale production facilities. To date several VTU customers have licensed and successfully scaled-up such processes for the manufacture of recombinant proteins with VTU´s Pichia system to volumes ranging from several hundred to more than 10,000 L.
An exclusive library of synthetic PAOX1 promoter variants – VTU´s highly approved 1st generation promoter variants – forms the core of VTU´s cutting-edge in-house Pichia pastoris toolbox enabling high-level protein production and secretion of more than 20 g/L for a variety of proteins by individual fine-tuning of expression. Notably, this library was complemented with groundbreaking and unique methanol-free 2nd generation PAOX1 promoter variants, facilitating strong expression even with just glycerol or glucose as the sole carbon source clearly outperforming conventional promoter systems. Major advantages of this new technology – besides abolishing toxic and explosive methanol as a substrate and retaining high expression levels of up to 15 g/L (e.g. for a cellulose hydrolyzing enzyme) – are reduced oxygen consumption and therefore significantly reduced heat production and cooling effort in fermentation as well as a significant potential to reduce process time and cost of goods.
The versatility and effectiveness of VTU´s Pichia system is further underlined by a set of proprietary expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput microscale screening and cultivation regime and effective fermentation protocols for maximization of product yield and overall process performance.
Meanwhile, the Pichia pastoris expression system has been established as a proven, safe (GRAS) and highly competitive expression system with strong secretory capacities while secreting only low amounts of endogenous proteins. Today, a large number of recombinant protein products (enzymes and biopharmaceuticals) on the market are produced in Pichia pastoris.
VTU´s Pichia pastoris toolbox
• VTU´s exclusive AOX1 promoter library for tunable, optimum protein expression
1st generation promoter library – MeOH induced processes
− Product yields of more than 20 g/L secreted protein
2nd generation promoter library – MeOH free processes
− Product yields up to 15 g/L secreted protein
− Glycerol or glucose as the sole carbon source
− Significantly less heat formation and cooling demand
− Safe and economically viable production processes
• Comprehensive in-house expression platform
• Set of proprietary expression enhancing helper factors
• Elaborated gene design and cloning/transformation strategies
• High-throughput cultivation and screening regime
• Excellent know-how in fermentation and downstream process development
Services for protein expression – accelerate time to market
• High speed expression strain development
• Upstream process development and optimization
• Downstream and analytical process development
• Small-scale production of purified non-GMP material
• Sound technology & data transfer to our customers
• Outlicensing opportunities for
- Human serum albumin (HSA)
- Human serum transferrin (HST)
- HSA-fusion proteins
- Cell culture proteins